News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Kazia Therapeutics.
RELATED STOCKHEAD STORIES
News
ASX Small Caps Lunch Wrap: Who else reckons we should kill it with fire?
Stockhead TV
V-Con: Small Cap Showcase – Companies set to perform and best bargains amidst turbulent market conditions
Health & Biotech
ASX Health Stocks: Kazia Therapeutics gets crucial designation status from the US FDA
Health & Biotech
ASX Health Stocks: Pro Medicus bags $32m deal, Kazia shows promise in child cancer drug
Health & Biotech
ASX Health Stocks: Alcidion wins Aussie government contract, while Resonance seeks US FDA nod
Health & Biotech
ASX Health Stocks: UBI partners with Mayo Clinic, while Medlab jumps 8pc after divestment
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ASX Health: Invex gets ready for Phase 3, Medlab gets US patent. Both jump 13pc this morning
Stockhead TV
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
Health & Biotech
As neuroscience blurs the line between tech and biology, these ASX brain health stocks are on the frontline
Health & Biotech
Kazia Therapeutics completes third licensing deal in seven weeks
Experts
ScoPo’s powerplays: Look to Mach7, Volpara and IMEXHS as quarterly reports near
Health & Biotech
HealthKick Podcast: Kazia tackles the curse of US politicians with its innovative drug candidate
Health & Biotech
Clinical Trials Tracker: 2022 and beyond
Health & Biotech
Clinical Trials Tracker: The tests ASX healthcare companies have upcoming in 2021
News
Last Orders: What you may have missed on the ASX today
News